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nonasal SCC (30% of total cost of care). The lifetime
cost of managing annual incident SCCHN cases was esti-
mated to approximate $976 million. CONCLUSION:
This study found that tumor stage and location are useful
predictors of increased treatment costs. The results sug-
gest that prevention and early detection are critical in re-
ducing the treatment costs of SCCHN.
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OBJECTIVES: Patients with thyroid carcinoma (TC) can
present a diagnostic dilemma when elevated tumormark-
ers (thyroglobulin, Tg) suggest relapse but whole body
131-iodine scanning (131I WBS) is negative. Then, bat-
tery of imaging modalities is available. In recent years,
positron emission tomography has been proposed as an
effective and comprehensive staging procedure. To esti-
mate the effort and yield of present clinical practice, we
performed a retrospective study. METHODS: From our
Tg database we identified all TC patients, and included
those with elevated Tg levels (&#61619; 1.5 pmol/l on
thyroid hormone medication) after ablation with 131I,
between 1-5-96 and 1-1-98, and recorded the applied di-
agnostic work-up. RESULTS: Tg data were identified
from 116 patients with TC. Twenty met the inclusion cri-
teria, 18 of which (90%) had a complicated work-up. Re-
current disease was confirmed in 16. The mean number
of imaging tests required to arrive at a clinical conclusion
was 5 (range 3–9), within a mean period of 18 months.
Since 1997, PET has been performed in 15 patients with
negative or equivocal high dose 131I WBS (8 positive and
7 negative scans). Tumor sites first disclosed by PET were
found in 5 patients. CONCLUSIONS: The current diag-
nostic trajectory in the majority of the patients with ele-
vated Tg and negative 131I WBS proved to be protracted
and complicated. Even though prognosis may not neces-
sarily be adversely affected by this delay, patient anxiety
is a considerable problem. FDG-PET may solve clinical
problems in some of these patients, but the currently
available evidence does not allow for implementation of
a routine diagnostic algorithm.
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OBJECTIVES: Since becoming widely recognized for its
antithrombotic effects in the 1970s, aspirin has become
first-line antiplatelet therapy across most patient popula-
tions. However, newer data suggests that clopidogrel is
more effective than aspirin for prevention of ischemic
events in peripheral artery disease (PAD) patients. In this
analysis, a decision analytic model was constructed in or-
der to evaluate the cost-effectiveness of clopidogrel versus
aspirin as prevention of ischemic events in patients with
established PAD. METHODS: Data on the probability of
ischemic events was extracted from the PAD subgroup of
the CAPRIE trial, in which event rates for clopidogrel
and aspirin were 3.71% and 4.86%, respectively. Costs
included in this analysis were obtained from the medical
literature. RESULTS: In the base case analysis, the ex-
pected cost of treatment over a one-year time frame with
clopidogrel and aspirin was $2075 and $1088, respec-
tively. Furthermore, to effectively treat one patient, it
would cost $2155 with clopidogrel and $1144 with aspi-
rin. An incremental cost-effectiveness analysis concluded
that one additional event of vascular death, MI, or
ischemic stroke will be prevented with clopidogrel at an
additional one-year cost of $85,826. A univariate sensi-
tivity analysis demonstrated that aspirin must have ischemic
event rates greater than 13% for clopidogrel to be the
preferred option based solely on cost. Furthermore, in or-
der for clopidogrel to be considered cost-effective with an
event rate of 3.71%, aspirin must have an event rate of
11.48%, a rate 2.4 times greater than was observed in
the CAPRIE trial. CONCLUSIONS: The result of this
analysis concluded that it would cost a third-party payer
an extra $85,826 to effectively treat one additional pa-
tient over a one-year period when using clopidogrel in-
stead of aspirin. This cost can play a major role in the de-
cision of appropriate antiplatelet therapy used to treat
PAD patients in the prevention of ischemic events.
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OBJECTIVES: The risk of VTE disease in patients under-
going major orthopedic surgery (MOS) has extensively
been studied in randomised clinical trials and more re-
cently in cohort studies. Our objective was to estimate
the risk of VTE disease in a much larger population and
to calculate its economic consequences in hospital.
METHODS: We conducted a retrospective study of the
risk of occurrence and associated costs of VTE compli-
cations (including deep vein thrombosis (DVT) and pul-
monary embolism (PE)) in patients undergoing MOS
(including hip replacement, hip fracture and knee re-
placement). Data were obtained from the National inpa-
tient Diagnosis Related Group (DRG) data base with ex-
